ϟ
DOI: 10.1016/j.jaad.2015.03.049
¤ OpenAccess: Green
This work has “Green” OA status. This means it may cost money to access on the publisher landing page, but there is a free copy in an OA repository.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp,Kristian Reich,Craig Leonardi,Leon Kircik,Sergio Chimenti,Richard Langley,C. Hu,R. Stevens,Robert M. Day,Kenneth B. Gordon,Neil J. Korman,C.E.M. Griffiths
Apremilast
Medicine
Placebo
2015
Loading...
- MLA
- APA
- Chicago
- IEEE
- Harvard
- BibTeX
Cite this:
Generate Citation
“Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)” is a paper by Kim Papp Kristian Reich Craig Leonardi Leon Kircik Sergio Chimenti Richard Langley C. Hu R. Stevens Robert M. Day Kenneth B. Gordon Neil J. Korman C.E.M. Griffiths published in 2015. It has an Open Access status of “green”. You can read and download a PDF Full Text of this paper here.